MedTrace Logo

Clinical Outcomes of Patients With Clostridium Difficile Associated Disease Attributable to Diverse tcdC Genotypes

NCT00446355 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2009-04-14

No results posted yet for this study

Summary

The purpose of the study is to establish the clinical disease outcomes and features of CDAD associated with variant tcdC genotypes. Two hypotheses are to be tested in this study:

1. Severe CDAD and tcdC truncation:

Severe CDAD (defined by death and/or colectomy or secondary endpoints) is associated with severe truncations (\> 6 amino acid residues) in TcdC, a negative regulator of toxin A/B production.
2. Disease in low risk populations (patients never exposed to health care facilities and/or patients who never received antibiotics) of any severity is attributable to strains of C. difficile with severe tcdC truncation.

Conditions

  • Clostridium Infections

Sponsors & Collaborators

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Scott Curry, MD · University of Pittsburgh

  • Lee Harrison, MD · University of Pittsburgh

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2009-04-30
Completion
2009-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00446355 on ClinicalTrials.gov